

Promotor	Institut National de la Santé et de la Recherche Médicale (Inserm)
Title	A French study describing of the management and persistency of patients with Idiopathic Pulmonary Fibrosis (IPF) treated with Esbriet [®] (pirfenidone) capsule or tablet: a specific research project from the RaDiCo-PID (Rare Disease Cohort – Pneumopathies Interstitielles Diffuses) cohort.
Country	France
Private partern	Roche Registration GmbH
Research Question and Objectives	<p>The primary objective for this study is as follows: To describe the patients' treatment with pirfenidone and the course of change of treatment between the two dosage forms will be described.</p> <p>The secondary objectives for this study are as follows: To describe the treatment persistency and description of patients (including sociodemographic and medical characteristics as well as quality of life) will be assessed.</p>
Population	The target study population will be sourced from patients recruited in RaDiCo-PID and will concern any IPF patient treated at least one time with Esbriet [®] between July 1st, 2017 and 30 June 2019.
Regulatory	Cohort RaDiCo-PID protocol, organized by Inserm, receiving a favorable opinion of Inserm Ethics Committee on 16 October 2015 and of CCTIRS on 23 March 2016. CNIL approved Cohort RaDiCo-PID protocol on 3 November 2016.